demonstrated that copper-chelating drugs increased the presence of tumor-infiltrating CD8+ T and NK cells, suggesting that reducing intratumoral copper levels could enhance anticancer immunotherapy efficacy (34). This evidence concerns the gene CD8A and neoplasm.